nature portfolio

Corresponding author(s):	Jens C. Brüning
Last updated by author(s):	Aug 23, 2023

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our Editorial Policies and the Editorial Policy Checklist.

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

Statistics

n/a	Co	onfirmed
	×	The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
	×	A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
	×	The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
	X	A description of all covariates tested
	×	A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
	×	A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
	×	For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i>) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted <i>Give P values as exact values whenever suitable.</i>
×		For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
×		For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
x		Estimates of effect sizes (e.g. Cohen's <i>d</i> , Pearson's <i>r</i>), indicating how they were calculated

Our web collection on statistics for biologists contains articles on many of the points above.

Software and code

Policy information about availability of computer code

Data collection

Indirect calorimetry: TSE PhenoMaster versions 6.2.5 and above

CT imaging: IVIS LivingImage Software (version 4.3.1)

qPCR analysis: QuantStudio Real-Time PCR software (version 1.7.1)

ELISA: Absorption spectroscopy was conducted using the SoftMax pro 6.3 software (Molecular Devices)

RNA concentration was measured with software ND-1000 (version 3.8.1)

Seahorse analysis: Wave 2.4.1 (Agilent)

Imaging of Western blots: FusionCapt Advance (Vilber)

Flow cytometry: MACSQuantify (version 2.13.1, Miltenyi Biotec)

 $\label{lem:microscopy:confocal images were acquired using a Leica SP8 microscope operated by LasX software (Leica) and the confocal images were acquired using a Leica SP8 microscope operated by LasX software (Leica) and the confocal images were acquired using a Leica SP8 microscope operated by LasX software (Leica) and the confocal images were acquired using a Leica SP8 microscope operated by LasX software (Leica) and the confocal images were acquired using a Leica SP8 microscope operated by LasX software (Leica) and the confocal images were acquired using a Leica SP8 microscope operated by LasX software (Leica) and the confocal image is a confocal image of the confocal image is a confocal image of the confocal image is a confocal image is a confocal image of the confocal image is a confocal i$

Brightfield images were acquired using Axio Imager 2 microscope operated by ZEN2 (blue edition; Carl Zeiss Microscopy GmbH).

 $TEM\ images\ of\ N43/5\ cells\ were\ acquired\ using\ software\ Digital Micrograph\ (Gatan,\ version\ 3.32.2403.0)$

Sphingolipidomics: QTRAP 6500 mass spectrometer was used operated by Analyst 1.6.3 (SCIEX) or Q-Exactive HRMS operated by Xcalibur software (Thermo Scientific)

(------

Data analysis General data visualization and analysis: Prism 9 (version 9.1.0, GraphPad) and Microsoft Excel (version 16.69.1)

ANCOVA analysis for energy expenditure of CerS6ΔNkx2.1 mice and controls: CalR Version 1.3 (https://calrapp.org/)

Analysis of body composition from CT images: Vinci software package (version 4.61.0)

Densitometric analysis and image quantification: ImageJ (Fiji) (version 2.9.0/1.53p13)

Sphingolipidomic analysis: MultiQuant 3.0.3 (SCIEX) and TraceFinder 5.1 (Thermo Scientific)

Seahorse analysis: Multi-File Seahorse XF Cell Mito Stress Test Report Generator (Agilent)

Flow cytometry: FlowJo software (BD Biosciences)

The HypoMap single cell data were analyzed using basic plotting functions (FeaturePlot, DotPlot) available through the R Seurat package and R. The associated R code can be made available upon request. Relevant software packages used for this analysis:

R (version 4.2.2)

Seurat R package (version 4.3.0) ggplot2 R package (version 3.4.0) dplyr R package (version 1.0.10)

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio guidelines for submitting code & software for further information.

Data

Policy information about availability of data

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our policy

Numerical data and uncropped immunoblots are available as Source Data file.

The seurat object containing HypoMap, which is required to reproduce the single-cell data related figures is available at University of Cambridge's Apollo Repository (doi:10.17863/CAM.87955). The R code used to analyze HypoMap single cell sequencing data is available under https://github.com/lsteuernagel/ceramide_paper_hypomap. The custom made semi-automatic ImageJ macros used to quantify pSTAT3 signal intensity from immunohistochemical stainings are available under https://github.com/mrfeldmann/ceramide_paper.

Human research participants

D 1:	the first of the control of the cont	the state of the s		
Policy information	about studies involving	human research participan	its and Sex and Gender in Research	

Reporting on sex and gender	N/A
Population characteristics	N/A
Recruitment	N/A
Ethics oversight	N/A

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Field-specific reporting

Please select the one below	w that is the best fit for your research	. If yo	u are not sure, read the appropriate sections before making your selection.
X Life sciences	Behavioural & social sciences		Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see nature.com/documents/nr-reporting-summary-flat.pdf

Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size

No statistical methods were used to pre-determine sample sizes. Sample sizes were based on own previous results and according to standards in the field. Sample sizes were similar to those reported previously: e.g., doi:10.1016/j.cell.2019.05.008.

Data exclusions

Sphingolipid data was tested for statistically significant outliers using Grubb's test (https://www.graphpad.com/quickcalcs/grubbs1/). Samples were only removed from the dataset if every acyl chain sphingolipid species of one sample was a significant outlier within the group.

Unreasonable jumps in food intake higher than 2g/20min, which occured likely due to technical errors during the PhenoMaster recordings, were removed from the dataset.

Other data were only excluded if obvious technical issues occured or because of euthanization of animals due to health complications in line with local animal guidelines.

Replication

Results from cultured cell lines are based on experiments that have been independently performed at least 3 times with one or more technical replicates per experiment, as specified in the figure legends. All attempts for replicates were successful. For metabolic phenotyping, every mouse represents a biological replicate (n) and the numbers are mentioned in each figure and/or figure

with the table premotyping, every mouse represents a stological represent (i) and the name of are mentioned in each right early or right.

legends. Mice were sequentially sampled, no formal replication study was performed. Blood glucose levels for CerS6ΔSF-1, CerS6ΔAgRP, and
CerS6ΔPOMC mice were measured in at least two repetitive measurements using two independent glucose monitors.

Randomization Sex and age-matched mice were allocated to their respective experimental groups based on their genotypes. Control and transgenic mice were littermates of different litters.

C57BL/6N mice used for the analysis of hypothalamic CerS expression and sphingolipid content were randomly assigned to the CD- and HFD-fed group.

For cellular assays, treatments were assigned in a random manner (e.g., it was random, which out of two culture plates was used for siCerS6-or scrambled treatment).

Blinding

The analysts performing TEM imaging and quantification of mitochondrial shape in POMC neurons as well as those performing sphingolipidomics were blinded for genotype and treatment until conditions were disclosed for data visualization.

For other experiments the analysts were blind for group allocation (genotype and treatment). However, no formal blinding practice was applied, since the persons planning and performing the experiments, and processing and analyzing the data were the same.

Behavioural & social sciences study design

All studies must disclose on these points even when the disclosure is negative. N/A Study description Research sample N/A Sampling strategy N/A Data collection N/A Timing N/A Data exclusions N/A Non-participation N/A Randomization N/A

Ecological, evolutionary & environmental sciences study design

All studies must disclose on these points even when the disclosure is negative.

Study description	N/A
Research sample	N/A
Sampling strategy	N/A
Data collection	N/A
Timing and spatial scale	N/A
Data exclusions	N/A
Reproducibility	N/A
Randomization	N/A
Blinding	N/A
Did the study involve fie	ld work? Yes X No

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

Materials & experime	ntal systems Methods
n/a Involved in the study	n/a Involved in the study
Antibodies	ChIP-seq
Eukaryotic cell lines	Flow cytometry
Palaeontology and a	archaeology MRI-based neuroimaging
Animals and other o	rganisms
Clinical data	
x Dual use research of	fconcern
Antibodies	
Antibodies used	Primary antibodies for Western blot analysis:
	Mouse monoclonal anti-CerS6 (5H7), (Abnova Cat# H00253782-M01, RRID:AB_489924, dilution 1:1000)
	Rabbit monoclonal anti-ATF4 (D4B8), (Cell Signaling Technology Cat# 11815, RRID:AB_2616025, dilution 1:1000)
	Rabbit polyclonal anti-Calnexin (575-593), (Millipore Cat#208880, RRID:AB_2069031, dilution 1:5000) Mouse monoclonal anti-ACTIN (AC-15), (Sigma-Aldrich Cat# A5441, RRID:AB_476744, dilution 1:10000)
	Goat polyclonal GRP78/BiP (N-20) (Santa Cruz Biotechnology Cat# sc1050, RRID:AB_631616, dilution 1:1000)
	Secondary antibodies for Western blot analysis: Goat polyclonal anti-rabbit IgG-peroxidase (Sigma-Aldrich Cat# A0545, RRID:AB_257896, dilution 1:2000)
	Goat polyclonal anti-nabilitigg-peroxidase (Sigma-Aldrich Cat# A0343, NRID:AB_257896, dilution 1:2000) Goat polyclonal anti-mouse IgG-peroxidase (Sigma-Aldrich Cat# A4416, RRID:AB_258167, dilution 1:2000)
	Mouse monoclonal anti-goat/sheep IgG-peroxidase (GT-34), (Sigma-Aldrich Cat# A9452, RRID:AB_258449, dilution 1:2000)
	Primary antibodies for flow-cytometry:
	Brilliant Violet 421™ anti-mouse/human CD11b Antibody, (M1/70), (BioLegend Cat# 101236, RRID:AB_11203704, dilution 1:150)
	O4 Antibody, anti-human/mouse/rat, APC (Miltenyi Biotec Cat# 130-119-155, RRID:AB_2751644, dilution 1:100)
	ACSA-2 Antibody, anti-mouse, APC, (IH3-18A3), (Miltenyi Biotec Cat# 130-117-535, RRID:AB_2727978, dilution 1:100))
	Primary antibodies for immunohistochemistry and transmission electron microscopy:
	Proopiomelanocortin Precursor (POMC) (27-52) antibody (Phoenix Pharmaceuticals Cat# H-029-30, RRID:AB_2307442, dilution
	1:7500) Phospho-Stat3 (Tyr705) (D3A7) XP Rabbit mAb antibody (Cell Signaling Technology Cat# 9145, RRID:AB_2491009, dilution 1:100)
	- 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1
	Secondary anithodies for immunohistochemistry and transmission electron microscopy:
	Anti-Rabbit IgG (Goat) antibody (MAb Technologies Cat# NEF812001EA, RRID:AB_2571640, dilution 1:100) Donkey Anti-Rabbit IgG (H+L) Antibody, Alexa Fluor 488 Conjugated, (A-21206), (Molecular Probes Cat# A-21206, RRID:AB_2535792,
	dilution 1:1000)
	Biotin-SP-AffiniPure Donkey Anti-Rabbit IgG (H+L) antibody (Jackson ImmunoResearch Labs Cat# 711-065-152, RRID:AB_2340593, dilution 1:250)
Validation	The CerS6 antibody was validated for Western blot analysis with CerS6-deficient mouse tissue and cultured cells in-house before
	(doi:10.1016/j.cell.2019.05.008).
	For all other antibodies please refer to the manufacturer's description of the antibodies:
	Mouse monoclonal anti-CerS6 (5H7) (Abnova Cat# H00253782-M01, RRID:AB_489924): https://www.abnova.com/protocol_pdf/DS_H00253782-M01.pdf
	Rabbit monoclonal anti-ATF4 (D4B8) (Cell Signaling Technology Cat# 11815, RRID:AB_2616025): https://www.cellsignal.com/datasheet.jsp?productId=11815&images=1&size=A4
	Rabbit polyclonal anti-Calnexin (575-593), (Millipore Cat#208880, RRID:AB_2069031): https://www.merckmillipore.com/DE/de/product/Anti-Calnexin-C-Terminal-575-593-Rabbit-pAb,EMD_BIO-208880#anchor_PDS
	Mouse monoclonal anti-ACTIN (AC-15), (Sigma-Aldrich Cat# A5441, RRID:AB_476744): https://www.sigmaaldrich.com/specification-sheets/141/510/A5441-BULKSIGMApdf
	Goat polyclonal GRP78/BiP (N-20) (Santa Cruz Biotechnology Cat# sc1050, RRID:AB_631616): https://datasheets.scbt.com/sc-1050.pdf

Goat polyclonal anti-rabbit IgG-peroxidase (Sigma-Aldrich Cat# A0545, RRID:AB_257896): https://www.sigmaaldrich.com/specification-sheets/327/941/A0545-BULK_____SIGMA___.pdf

Goat polyclonal anti-mouse IgG-peroxidase (Sigma-Aldrich Cat# A4416, RRID:AB_258167): https://www.sigmaaldrich.com/

specification-sheets/200/206/A4416-BULK____SIGMA___.pdf

Mouse monoclonal anti-goat/sheep IgG-peroxidase, clone GT-34 (Sigma-Aldrich Cat# A9452, RRID:AB_258449): https://www.sigmaaldrich.com/specification-sheets/393/427/A9452-BULK_______SIGMA_____.pdf

Brilliant Violet 421™ anti-mouse/human CD11b Antibody, (M1/70), (BioLegend Cat# 101236, RRID:AB_11203704):

https://d1spbj2x7qk4bg.cloudfront.net/Default.aspx?

 $ID=10267\&pdf=true\&displayInline=true\&ProductID=7163\&leftRightMargin=15\&topBottomMargin=15\&filename=Brilliant\%20Violet\%20421^{m}\%20anti-mouse/human\%20CD11b\%20Antibody.pdf\&v=20230524063105$

O4 Antibody, anti-human/mouse/rat, APC (Miltenyi Biotec Cat# 130-119-155, RRID:AB_2751644): https://static.miltenyibiotec.com/asset/150655405641/document_og3ujsnjot4jf5l429vn663b0r?content-disposition=inline

ACSA-2 Antibody, anti-mouse, APC, (IH3-18A3), (Miltenyi Biotec Cat# 130-117-535, RRID:AB_2727978): https://static.miltenyibiotec.com/asset/150655405641/document_ovasi59abl6oj5cjb8dtm2ko3m?content-disposition=inline

Proopiomelanocortin Precursor (POMC) (27-52) antibody (Phoenix Pharmaceuticals Cat# H-029-30, RRID:AB_2307442): https://www.phoenixpeptide.com/products/view/Antibodies/H-029-30

Phospho-Stat3 (Tyr705) (D3A7) XP Rabbit mAb antibody (Cell Signaling Technology Cat# 9145, RRID:AB_2491009): https://www.cellsignal.com/datasheet.jsp?productId=9145&images=1&size=A4

Anti-Rabbit IgG (Goat) antibody (MAb Technologies Cat# NEF812001EA, RRID:AB_2571640): https://stella.mabtech.com/sites/default/files/product_datasheets/3310-7-1000.pdf

Donkey Anti-Rabbit IgG (H+L) Antibody, Alexa Fluor 488 Conjugated, (A-21206) (Molecular Probes Cat# A-21206, RRID:AB_2535792): https://www.thermofisher.com/order/genome-database/dataSheetPdf? producttype=antibody&productsubtype=antibody_secondary&productId=A-21206&version=320

Biotin-SP-AffiniPure Donkey Anti-Rabbit IgG (H+L) antibody (Jackson ImmunoResearch Labs Cat# 711-065-152, RRID:AB_2340593): https://www.jacksonimmuno.com/catalog/products/711-065-152

Mouse monoclonal anti-goat/sheep IgG-peroxidase, (GT-34), (Sigma-Aldrich Cat# A9452, RRID:AB_258449): https://www.sigmaaldrich.com/specification-sheets/298/716/SAB4200804-BULK____sIGMA_____.pdf

Eukaryotic cell lines

Cell line source(s)

Policy information about cell lines and Sex and Gender in Research

oney information about <u>cell lines and Sex and Gender in Research</u>

For in vitro experiments we employed the immortalized embryonic mouse hypothalamus cell line N43/5 (mHypoE-N43/5), which was derived originally from a POMC-positive fetal hypothalamic neuron as described previously by D.D. Belsham

(doi:10.1677/JOE-06-0080).

Authentication The cell line has not been authenticated in the current study.

Mycoplasma contamination The cell line was tested negative for mycoplasma contamination.

Commonly misidentified lines (See ICLAC register)

No commonly misidentifed cell lines were used in this study.

Animals and other research organisms

Policy information about <u>studies involving animals</u>; <u>ARRIVE guidelines</u> recommended for reporting animal research, and <u>Sex and Gender in Research</u>

Laboratory animals

C57BL/6N male mice (strain code: 027) were purchased from Charles River laboratories at 4 weeks of age.

db/db male mice and misty controls were purchased from The Jackson Laboratory.

CerS6Δ/Δ mice (doi:10.1016/j.cmet.2014.08.002) were obtained from in-house breedings.

For hypothalamic ablation, CerS1fl/fl (doi:10.1016/j.celrep.2018.12.031) and CerS6fl/fl mice (doi:10.1016/j.cmet.2014.08.002) were bred to mice expressing the Nkx2.1-Cre transgene (doi:10.1002/cne.21529). CerS6fl/fl animals were also bred to previously described SF-1-Cre (doi:10.1016/j.neuron.2005.12.021), AgRP-IRES-Cre (doi:10.1038/nn.2167), and POMC-Cre-expressing mice (doi:10.1016/j.neuron.2004.06.004). Mice between 4-43 wk were used for experiments. Specific age of mice for each experiment is described in Methods.

For detailed information on mouse husbandry and animal care, we refer the reader to the Methods section of the manuscript.

Wild animals

No wild animals were used in this study.

Reporting on sex

Male and female mice were analyzed separately. Sex of mice is specified in the figure legends and in the body weight graphs.

Field-collected samples

No field-collected samples were used in this study.

Ethics oversight	All animal procedures were conducted in compliance with protocols approved by local government authorities (Bezirksregierung
Ethics oversight	Köln). Permission to maintain and breed mice as well as for all experimental protocols in this study was issued by the Department for
	Environment and Consumer Protection - Veterinary Section, Köln, North Rhine-Westphalia, Germany .
Note that full information on	the approval of the study protocol must also be provided in the manuscript.
Clinical data	
Policy information about g	clinical studies ly with the ICMJEguidelines for publication of clinical research and a completed CONSORT checklist must be included with all submissions.
Clinical trial registration	N/A
Study protocol	N/A
Data collection	N/A
Outcomes	N/A
Dual use researc	h of concern
Policy information about	dual use research of concern
Hazards	
	eliberate or reckless misuse of agents or technologies generated in the work, or the application of information presented
in the manuscript, pose	a threat to:
No Yes	
Public health National security	
Crops and/or live	
Ecosystems	SCOCK CONTRACTOR OF THE PROPERTY OF THE PROPER
Any other signific	rant area
Any other signific	and died
Experiments of conce	ern ern
Does the work involve a	any of these experiments of concern:
No Yes	
	w to render a vaccine ineffective
	e to therapeutically useful antibiotics or antiviral agents
	lence of a pathogen or render a nonpathogen virulent
	ssibility of a pathogen
	nge of a pathogen
	f diagnostic/detection modalities
	onization of a biological agent or toxin
∐	tially harmful combination of experiments and agents
ChIP-seq	
Data deposition	

Confirm that both raw and fi	nal processed data have been deposited in a public database such as GEO.
Confirm that you have depos	ited or provided access to graph files (e.g. BED files) for the called peaks.
Data access links May remain private before publication.	N/A
Files in database submission	N/A
Genome browser session (e.g. <u>UCSC</u>)	N/A

Methodology	
	N/A
Sequencing depth	N/A
Antibodies	N/A
Peak calling parameters	N/A
Data quality	N/A
. ,	N/A
Flow Cytometry	
Plots	
	e marker and fluorochrome used (e.g. CD4-FITC). Irly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).
	ots with outliers or pseudocolor plots.
	number of cells or percentage (with statistics) is provided.
Methodology	
Sample preparation	Adult mouse hypothalami were dissociated using the Adult Brain Dissociation Kit for mouse and rat (#130-107-677, Miltenyi Biotec) in combination with the gentleMACS Octo Dissociator with Heaters (#130-096-427, Miltenyi Biotec) according to the manufacturer's instructions. Separation of neuronal and non-neuronal cell fractions was performed using the Neuron Isolation Kit for mouse (#130-115-389, Miltenyi Biotec) according to the manufacturer's instructions. For more details we refer to the reador to the Methods section in the manuscript.
Instrument	MACSQuant 10 (Miltenyi Biotec).
Software	MACSQuantify (version 2.13.1, Miltenyi Biotec) and FlowJo software (BD Biosciences).
Cell population abundance	No rare cell populations were investigated.
Gating strategy	Dead cells were excluded based on propidium iodide fluorescence.
Tick this box to confirm	n that a figure exemplifying the gating strategy is provided in the Supplementary Information.
Magnetic recepan	oo imaging
Magnetic resonan	ce inaging
Experimental design	N/A
Design type	N/A
Design specifications	N/A
Behavioral performance meas	sures N/A
Acquisition	
Imaging type(s)	N/A
Field strength	N/A
Sequence & imaging paramet	ers N/A
Area of acquisition	N/A
Diffusion MRI	Jsed Not used
Preprocessing	

N/A

Preprocessing software

ומנטות	20+ 50 5
ומסונווע	2007:00
041111101	

S	ζ	•	
3			
١			
		?	
`		•	

Normalization	N/A	A			
Normalization template	N/A				
Noise and artifact removal	N/A				
Volume censoring	N/A				
tatistical modeling & infere	ence				
Model type and settings	N/A				
Effect(s) tested	N/A				
Specify type of analysis: W	hole brain	ROI-based Both			
Statistic type for inference (See <u>Eklund et al. 2016</u>)	N/A				
Correction	N/a				
Models & analysis					
n/a Involved in the study	·	sis			
Functional and/or effective connecti	ivity	cy N/A			
Graph analysis	N/A				
Multivariate modeling and predictive analysis		N/A			